iSAM Funds (UK)’s Myriad Genetics MYGN Stock Holding History

iSAM Funds (UK)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-31,653	Closed	-$229K	–	569
2025 Q3	$229K	Buy	+31,653	New	+$188K	0.05%	394

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

iSAM Funds (UK)'s MYGN Position: Q4 2025 in Review

iSAM Funds (UK) sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 31,653 shares — an estimated $229K sold.

iSAM Funds (UK) first reported a position in MYGN in Q3 2025 and held it in 1 quarter. The position peaked at $229K in Q3 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

iSAM Funds (UK) reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
iSAM Funds (UK) sold 31,653 Myriad Genetics shares in Q4 2025, an estimated $229K.
iSAM Funds (UK) first reported a position in Myriad Genetics in Q3 2025 and held it in 1 quarter.
iSAM Funds (UK)'s Myriad Genetics position peaked at $229K in Q3 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on iSAM Funds (UK)'s 13F filing for Q4 2025, filed 17 Feb 2026.